Greenphire, a provider of payment technologies for the clinical trials industry, announced a relationship with Oracle Health Sciences.
Greenphire
, a provider of payment technologies for the clinical trials industry, announced a relationship with
Oracle Health Sciences
. Oracle and Greenphire are integrating their respective product suites to enable their clients to streamline and automate processes from trial planning and budgeting, all the way through data capture to executing payments to clinical sites and patients, while providing real-time, strategically valuable reporting and analytics.
The first initiative will be the integration of Greenphire’s global payment platform, eClinicalGPS, with Oracle’s electronic data capture (EDC) solutions, Oracle Health Sciences InForm and Oracle Remote Data Capture (RDC). This integration will help ensure that clients have quick product implementations without relying on internal development and staffing. Data sharing between EDC and payment technologies will enable a virtually seamless transition between the collection and capture of clinical data and the accurate execution of payments. Greenphire and Oracle are currently working with three joint clients including two top 10 global biopharmaceutical clients and a fast growing biotechnology client.
“Clinical trial sponsors and their CRO partners are focused on improving productivity and efficiency across their clinical programs – including study set up, recruitment, data collection and analysis, as well as the administration of and payments to research sites and participants. Integrations between the Oracle and Greenphire product suites can help biopharmaceutical companies and CROs achieve new levels of efficiency and deliver powerful analytics that support continuous improvement. This will enable companies to re-direct freed up resources to discovery and development initiatives,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences.
“Greenphire is committed to continually finding ways to increase efficiencies in clinical research processes and to drive value andcost savings for our clients,” said Greenphire Founder & CEO Sam Whitaker, “Our relationship with Oracle is a tremendous opportunity to find innovative ways to streamline existing processes and to ultimately simplify financial planning and management of clinical trials, by working with a company that offers world-class e-clinical solutions.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.